Protox Initiates Phase 2 Prostate Cancer Study

Protox Therapeutics Inc. (TSXV:PRX) has reported a positive Phase 1 memorize on its PRX302 drug seeker after benign prostatic hyperplasia, a everyday condition amidst aging males.. Vancouver, BC, January 15, 2008--Protox Therapeutics today announced that the Company has received Institutional Review Board approvals to proceed with its Phase 2a clinical proof evaluating PRX302 after the treatment of localized . 3 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V: PRX), aleader in advancing novel, targeted protein toxin therapeutics after thetreatment of cancer and other proliferative diseases, today announced positivefinal results from its Phase 1 . Vancouver, BC, January 15, 2008--Protox Therapeutics today announced that the Company has received Institutional Review Board approvals to proceed with its Phase 2a clinical proof evaluating PRX302 after the treatment of localized . 3 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V: PRX), aleader in advancing novel, targeted protein toxin therapeutics after thetreatment of cancer and other proliferative diseases, today announced positivefinal results from its Phase 1 . VANCOUVER - Protox Therapeutics Inc. (TSXV:PRX) has reported a positive Phase 1 memorize on its PRX302 drug seeker after benign prostatic hyperplasia, a everyday condition amidst aging males. Protox said Thursday that results from the proof . 15 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX), a leaderin the happening of targeted therapeutic proteins, today announced that theCompany has received Institutional Review Board (IRB) approvals to proceedwith its Phase 2a clinical . VANCOUVER - Protox Therapeutics Inc. (TSXV:PRX) has reported a positive Phase 1 memorize on its PRX302 drug seeker after benign prostatic hyperplasia, a everyday condition amidst aging males. Protox said Thursday that vitamin results from the proof .